AD projects in Dr. Landreth’s laboratory are directed at understanding how the beta-amyloid peptides are normally cleared from the brain and the roles of inflammation in AD pathogenesis. The lab is also engaged in identification and validation of new therapeutic agents for the treatment of AD.  Dr. Landreth received his B.A. from the University of Kansas, and his Ph.D. from the University of Michigan.